Trade

with

Biogen Idec Inc
(NASDAQ: BIIB)
AdChoices
326.77
+15.36
+4.93%
After Hours :
326.77
0.00
0.00%

Open

320.46

Previous Close

311.41

Volume (Avg)

1.38M (1.18M)

Day's Range

316.03-326.90

52Wk Range

230.25-358.89

Market Cap.

73.54B

Dividend Rate ( Yield )

-

Beta

1.23

Shares Outstanding

236.14M

P/E Ratio (EPS)

34.60 (8.99)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 6.93B

    • Net Income

    • 1.86B

    • Market Cap.

    • 73.54B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 25.64

    • PEG (Price/Earnings Growth) Ratio

    • 1.29

    • Beta

    • 1.23

    • Forward P/E

    • 18.52

    • Price/Sales

    • 8.87

    • Price/Book Value

    • 7.69

    • Price/Cash flow

    • 28.09

      • EBITDA

      • 3.04B

      • Return on Capital %

      • 18.01

      • Return on Equity %

      • 24.50

      • Return on Assets %

      • 18.01

      • Book Value/Share

      • 40.49

      • Shares Outstanding

      • 236.14M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 430.00

        • Credit Rating

        • AA-

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 47.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 34.90

          • 17.04

          • Net Income

            Q/Q (last year)

          • 45.60

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 11.09

          • 63.43

          • Net Income

            5-Year Annual Average

          • 18.90

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 87.25

            • 82.75

            • Pre-Tax Margin

            • 35.85

            • 39.38

            • Net Profit Margin

            • 25.64

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 90.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 32.00

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 24.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.06

              • 0.76

              • Current Ratio

              • 2.05

              • 2.92

              • Quick Ratio

              • 1.49

              • 2.35

              • Interest Coverage

              • 109.01

              • 38.02

              • Leverage Ratio

              • 1.35

              • 2.21

              • Book Value/Share

              • 40.49

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 34.60

                • 238.10

                • P/E Ratio 5-Year High

                • 39.90

                • 634.30

                • P/E Ratio 5-Year Low

                • 4.64

                • 124.82

                • Price/Sales Ratio

                • 8.87

                • 8.94

                • Price/Book Value

                • 7.69

                • 8.12

                • Price/Cash Flow Ratio

                • 28.09

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 24.50

                    (19.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 18.01

                    (13.80)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 23.00

                    (16.60)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 312.32k

                  • 117.08k

                  • Inventory Turnover

                  • 1.65

                  • 1.48

                  • Asset Turnover

                  • 0.70

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  2.52B
                  Operating Margin
                  36.29
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  28.09
                  Ownership

                  Institutional Ownership

                  94.71%

                  Top 10 Institutions

                  45.11%

                  Mutual Fund Ownership

                  58.18%

                  Float

                  89.74%

                  5% / Insider Ownership

                  0.77%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard PrimeCap Fund

                  •  

                    9,973,695

                  • -0.99

                  • 4.20

                  • Fidelity® Contrafund® Fund

                  •  

                    8,238,199

                  • 2.04

                  • 3.49

                  • Vanguard Total Stock Mkt Idx

                  •  

                    3,866,612

                  • 0.44

                  • 1.64

                  • VA CollegeAmerica Growth Fund of America

                  •  

                    3,452,200

                  • -11.37

                  • 1.46

                  • ClearBridge Aggressive Growth Fund

                  •  

                    3,292,304

                  • 0.00

                  • 1.39

                  • Vanguard Capital Opportunity Fund

                  •  

                    2,765,438

                  • -0.72

                  • 1.17

                  • T. Rowe Price Growth Stock Fund

                  •  

                    2,720,000

                  • -1.28

                  • 1.15

                  • Vanguard Five Hundred Index Fund

                  •  

                    2,451,596

                  • -0.21

                  • 1.04

                  • Vanguard Institutional Index Fund

                  •  

                    2,392,392

                  • -1.50

                  • 1.01

                  • SPDR® S&P 500 ETF

                  •  

                    2,353,129

                  • -1.10

                  • 0.92

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    21,066,939

                  • -3.71%

                  • 8.88

                  • PRIMECAP Management Company

                  •  

                    17,258,311

                  • -1.39%

                  • 7.28

                  • T. Rowe Price Associates, Inc.

                  •  

                    12,194,641

                  • +0.14%

                  • 5.14

                  • Vanguard Group, Inc.

                  •  

                    12,086,297

                  • +1.57%

                  • 5.10

                  • State Street Corp

                  •  

                    9,638,717

                  • +0.96%

                  • 4.06

                  • Capital Research Global Investors

                  •  

                    8,198,550

                  • -4.04%

                  • 3.46

                  • ClearBridge Advisors, LLC

                  •  

                    7,893,874

                  • +2.47%

                  • 3.33

                  • BlackRock Fund Advisors

                  •  

                    7,271,790

                  • +2.08%

                  • 3.07

                  • Jennison Associates LLC

                  •  

                    6,280,884

                  • -0.89%

                  • 2.65

                  • J.P. Morgan Investment Management Inc.

                  •  

                    5,081,303

                  • +14.70%

                  • 2.14

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Aggressive Growth

                  Style

                  Large Growth

                  Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company focused. It discovers, develops, manufactures and markets therapies for the treatment of...more multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve...more cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.lessless

                  Key People

                  Dr. George A. Scangos,PhD

                  CEO/Director

                  Dr. Stelios Papadopoulos,PhD

                  Director/Chairman of the Board

                  Mr. Paul J. Clancy

                  CFO/Executive VP, Divisional

                  Dr. Douglas E. Williams,PhD

                  Executive VP, Divisional

                  Steven H. Holtzman

                  Executive VP, Divisional

                  • Biogen Idec Inc

                  • 225 Binney Street

                  • Cambridge, MA 02142

                  • USA.Map

                  • Phone: +1 617 679-2000

                  • Fax: -

                  • biogenidec.com

                  Incorporated

                  1985

                  Employees

                  6,850

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: